1. Home
  2. STLA vs RMD Comparison

STLA vs RMD Comparison

Compare STLA & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stellantis N.V.

STLA

Stellantis N.V.

HOLD

Current Price

$11.96

Market Cap

31.6B

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$252.93

Market Cap

36.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STLA
RMD
Founded
2021
1989
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.6B
36.4B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
STLA
RMD
Price
$11.96
$252.93
Analyst Decision
Hold
Buy
Analyst Count
5
13
Target Price
$11.99
$292.27
AVG Volume (30 Days)
12.5M
893.0K
Earning Date
07-29-2025
01-29-2026
Dividend Yield
4.90%
0.95%
EPS Growth
N/A
29.59
EPS
N/A
9.77
Revenue
$171,605,402,237.00
$5,257,400,000.00
Revenue This Year
N/A
$9.85
Revenue Next Year
$5.33
$7.32
P/E Ratio
N/A
$25.82
Revenue Growth
N/A
9.36
52 Week Low
$8.39
$199.92
52 Week High
$14.28
$293.81

Technical Indicators

Market Signals
Indicator
STLA
RMD
Relative Strength Index (RSI) 63.15 48.94
Support Level $11.71 $250.37
Resistance Level $12.15 $259.99
Average True Range (ATR) 0.25 5.54
MACD 0.10 0.57
Stochastic Oscillator 87.50 63.20

Price Performance

Historical Comparison
STLA
RMD

About STLA Stellantis N.V.

Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Share on Social Networks: